Lumida
/FATE
⌘K
Fate Therapeutics Inc

Fate Therapeutics Inc

FATE
$2.31USD-0.86%-0.02 today

MARKET CAP

276.8M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
Buy NowMedium

Stock is in a Stage 2 uptrend medium-term bullish environment, showing a pullback into rising EMAs that have held support, offering a timely buy opportunity despite a Bullish Exhaustion pattern that signals possible short-term fatigue.

  • RECLAIM-LN Phase 2 trial for FT819 in SLE launched; first patient dosed.
  • $153.8M cash as of June 30 2026 funds operations into 2028.
  • Q2 2026 net loss $30M and EPS –$0.25 reflect ongoing losses.
Full analysis →
Insider Trades21 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Aug 4, 2026SellFATECindy Tahl38,800$2.46$276.8M-28.48%+145.72%$95.4K-6.18%Buy Now
Aug 4, 2026SellFATEBahram ValamehrPresident and CEO43,947$2.46$276.8M-28.48%+145.72%$108.1K-6.91%Buy Now
May 20, 2026SellFATECindy Tahl25,590$1.88$276.8M-28.48%+145.72%$48.1K-3.91%Buy Now
May 20, 2026SellFATEBahram ValamehrPresident and CEO28,946$1.88$276.8M-28.48%+145.72%$54.5K-4.35%Buy Now
May 6, 2026BuyFATECindy Tahl166,664$1.25$276.8M-28.48%+145.72%$208.0K+10.39%Buy Now
Jan 9, 2026SellFATEBahram ValamehrPresident and CEO5,190$1.07$276.8M-28.48%+145.72%$5.6K-1.55%Buy Now
Jan 9, 2026SellFATECindy Tahl10,589$1.06$276.8M-28.48%+145.72%$11.3K-2.66%Buy Now
Aug 4, 2025SellFATECindy Tahl9,037$1.06$276.8M-28.48%+145.72%$9.6K-2.22%Buy Now
Aug 4, 2025SellFATEBahram ValamehrPresident and CEO14,466$1.06$276.8M-28.48%+145.72%$15.4K-4.14%Buy Now
Jan 10, 2025SellFATECindy Tahl5,654$1.55$276.8M-28.48%+145.72%$8.8K-1.65%Buy Now
Jan 10, 2025SellFATEJerome Charles Bressi5,980$1.55$276.8M-28.48%+145.72%$9.3K-2.17%Buy Now
Jan 10, 2025SellFATEBahram ValamehrPresident and CEO8,705$1.54$276.8M-28.48%+145.72%$13.4K-2.43%Buy Now
Mar 4, 2024SellFATEEdward J Iii DulacChief Financial Officer2,447$7.77$276.8M-28.48%+145.72%$19.0K-2.35%10b5-1Buy Now
Jan 29, 2024SellFATEEdward J Iii DulacChief Financial Officer1,849$5.00$276.8M-28.48%+145.72%$9.2K-1.75%10b5-1Buy Now
Jan 9, 2024SellFATEEdward J Iii DulacChief Financial Officer7,028$4.37$276.8M-28.48%+145.72%$30.7K-6.23%Buy Now
Jan 9, 2024SellFATECindy TahlGeneral Counsel and Secretary10,874$4.37$276.8M-28.48%+145.72%$47.5K-7.10%Buy Now
Jan 9, 2024SellFATEBahram ValamehrChief R&D Officer11,271$4.38$276.8M-28.48%+145.72%$49.4K-6.66%Buy Now
Jan 9, 2024SellFATEJ Scott WolchkoPresident and CEO14,391$4.37$276.8M-28.48%+145.72%$62.9K-3.73%Buy Now
Jan 2, 2024SellFATEEdward J Iii DulacChief Financial Officer5,182$3.66$276.8M-28.48%+145.72%$19.0K-4.39%10b5-1Buy Now
Dec 18, 2023SellFATEEdward J Iii DulacChief Financial Officer1,585$3.50$276.8M-28.48%+145.72%$5.5K-1.33%10b5-1Buy Now
Nov 9, 2023SellFATECindy TahlGeneral Counsel and Secretary24,363$2.40$276.8M-28.48%+145.72%$58.5K-13.72%10b5-1Buy Now